Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphoma

New Agents for Mantle Cell LymphomaПодробнее

A Phase I/II trial of glofitamab monotherapy in R/R MCLПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

Expert Reviews Treatment Landscape for Patients With Mantle Cell LymphomaПодробнее

GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCLПодробнее

Tycel Phillips, MD, on Glofitamab Research, Progress in Mantle Cell LymphomaПодробнее

Glofitamab & Pirtobrutinib for Relapsed/Refractory Mantle Cell Lymphoma -Blood Cancers Video LibraryПодробнее

Glofitamab as a single agent in heavily pretreated patients with DLBCLПодробнее

Glofitamab and obinutuzumab in r/r MCLПодробнее

The role of targeted therapies in the frontline treatment of mantle cell lymphomaПодробнее

The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & moreПодробнее

Promising agents being explored in R/R MCL: bispecific antibodies and BTK inhibitorsПодробнее

Updates on glofitamab in MCLПодробнее

Mantle Cell Lymphoma (Case Studies)Подробнее

Standard Regimens and Novel Agents for Mantle Cell LymphomaПодробнее

Rule Discusses the Potential of Zanubrutinib in the Treatment of Mantle Cell LymphomaПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Understanding Mantle Cell Lymphoma with Jia Ruan, MD, Ph.D.Подробнее

Selecting between BTK inhibitors in MCL & addressing resistance to these agentsПодробнее